💨 Abstract

AstraZeneca plans to build a multi-billion-dollar manufacturing plant in Virginia, the largest investment in its global expansion. The facility will produce weight management and metabolic drugs leveraging AI and automation. This move aligns with the company's goal of generating 50% of its revenue in the U.S. by 2030, amidst broader industry pressure for domestic manufacturing.

Courtesy: Jeff Clabaugh